Literature DB >> 7510760

Retinoblastoma protein monoclonal antibodies with novel characteristics.

S F Wen1, M Nodelman, K Nared-Hood, J Duncan, J Geradts, H M Shepard.   

Abstract

We have developed a family of monoclonal antibodies directed against the retinoblastoma gene product (p110RB). One of these monoclonal antibodies, 3C8, binds p110RB near the C-terminal end of the protein (aa886-aa905). It was characterized by immunoblotting, ELISA, fluorescence-activated flow cytometry and immunohistostaining. It was shown to be useful for the detection of p110RB in formalin-fixed and paraffin-embedded tissue sections. Because 3C8 binds outside of regions shown to be involved in p110RB interactions with other cellular proteins, it may be an especially useful reagent for the reliable detection of p110RB in tumor cells, and for the isolation by affinity chromatography of p110RB complexes with other cellular proteins.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7510760     DOI: 10.1016/0022-1759(94)90267-4

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  4 in total

1.  Inhibition of the cyclin D1/E2F pathway by PCA-4230, a potent repressor of cellular proliferation.

Authors:  D Goukassian; S M Sanz-González; I Pérez-Roger; J Font de Mora; J Ureña; V Andrés
Journal:  Br J Pharmacol       Date:  2001-04       Impact factor: 8.739

2.  Characterization of a new human glioblastoma cell line that expresses mutant p53 and lacks activation of the PDGF pathway.

Authors:  R A Gjerset; H Fakhrai; D L Shawler; S Turla; O Dorigo; A Grover-Bardwick; D Mercola; S F Wen; H Collins; H Lin
Journal:  In Vitro Cell Dev Biol Anim       Date:  1995-03       Impact factor: 2.416

3.  High frequency of aberrant p16(INK4A) expression in human breast cancer.

Authors:  J Geradts; P A Wilson
Journal:  Am J Pathol       Date:  1996-07       Impact factor: 4.307

4.  Independent prognostic significance of cell cycle regulator proteins p16(INK4a) and pRb in advanced-stage ovarian carcinoma including optimally debulked patients: a translational research subprotocol of a randomised study of the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group.

Authors:  S Kommoss; A du Bois; R Ridder; M J Trunk; D Schmidt; J Pfisterer; F Kommoss
Journal:  Br J Cancer       Date:  2007-01-29       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.